Form 4: Cognition Therapeutics CMO Anthony Caggiano Buys Shares

Sentiment:

Statement of Changes in Beneficial Ownership


Chief Medical Officer Anthony Caggiano acquired 10,000 shares of Cognition Therapeutics common stock at $1.11 per share.

Summary

  • Anthony Caggiano, Chief Medical Officer of Cognition Therapeutics, purchased 10,000 shares of common stock.
  • The transaction occurred on April 16, 2026, at a price of $1.11 per share.
  • Following this acquisition, the reporting person's total beneficial ownership increased to 874,906 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as executive ownership alignment typically suggests confidence in the company's strategic direction.

Positives

  • Insider confidence is demonstrated by the Chief Medical Officer's decision to increase his equity stake in the company.
  • The purchase of 10,000 shares at $1.11 indicates management's commitment to the company's long-term value.

Negatives

  • NA

Risks

  • NA

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider buying in the biotechnology sector is often viewed as a positive signal regarding the internal assessment of clinical trial progress or upcoming milestones.

Comparison to Industry Standards

  • Insider buying is generally considered a bullish indicator compared to the broader market, where executive selling is more common for liquidity purposes.

Stakeholder Impact

  • Shareholders may interpret this purchase as a sign of management's confidence in the company's future prospects.

Next Steps

  • NA

Key Dates

DateDescription
04/16/2026Date of the stock purchase transaction.
04/20/2026Date the Form 4 was signed and filed.

Keywords

CGTX, Cognition Therapeutics, Insider Trading, Form 4, Biotech, Chief Medical Officer

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.